Most A-Fib Patients Have at Least One Identifiable Trigger
FRIDAY, Feb. 15, 2019 -- Most patients with atrial fibrillation (AF) report at least one identifiable trigger, with the most common triggers being alcohol, caffeine, exercise, and lack of sleep, according to research published online Feb. 14 in... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - February 15, 2019 Category: Pharmaceuticals Source Type: news

Screening for Atrial Fibrillation: The Debate
(MedPage Today) -- Limited evidence contributes to controversy (Source: MedPage Today Cardiovascular)
Source: MedPage Today Cardiovascular - February 15, 2019 Category: Cardiology Source Type: news

Everyday'Triggers' May Bring on A-Fib Episodes, Study Finds
THURSDAY, Feb. 14, 2019 -- Many older Americans are diagnosed with the irregular heartbeat known as atrial fibrillation, or " a-fib. " Now, research suggests that everyday foods, drinks or activities might trigger episodes of the stroke-linked... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - February 14, 2019 Category: General Medicine Source Type: news

New antibiotic prescribing guidance for suspected pneumonia
Draft antibiotic prescribing guidance developed by NICE and PHE Related items fromOnMedica Uncertainty remains over effectiveness of steroids for sore throat Provisional green light for anti-clotting drug and quality standard for atrial fibrillation Antenatal flu drugs not linked to newborn risks Include pregnant women in studies, urge researchers Quarter million people taking benzodiazepines for more than a year (Source: OnMedica Latest News)
Source: OnMedica Latest News - February 13, 2019 Category: UK Health Source Type: news

AtriCure launches CryoIce CryoSphere probe
AtriCure (NSDQ:ATRC) today launched its CryoIce CryoSphere probe in the U.S. The Mason, Ohio-based company’s CryoSphere probe is designed to block pain by temporarily ablating peripheral nerves. The device features a bendable distal shaft and an ergonomic handle that enables cardiac, thoracic and general surgeons to easily target peripheral nerves. ArtiCure’s CryoSphere technology uses a freezing method to stop nerves from sending pain signals for several months, giving the patient’s body time to heal. “The addition of the CryoSphere probe to our pain management portfolio is a major breakthroug...
Source: Mass Device - February 12, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Featured Pain Management Wall Street Beat AtriCure Inc. Source Type: news

Studies Support Causal Role for Thyroid Disease in AFib Studies Support Causal Role for Thyroid Disease in AFib
Previous research has linked thyroid disease to atrial fibrillation. Two new studies use genetic approaches to fine-tune and confirm the association.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - February 12, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Ten Thoughts on the 2019 AF Treatment Guidelines Ten Thoughts on the 2019 AF Treatment Guidelines
John Mandrola, MD, agrees with a lot of the updates in the new atrial fibrillation guidelines but worries that color-coded tables of recommendations oversimplify the nuances of clinical decision making.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2019 Category: Consumer Health News Tags: Cardiology Expert Column Source Type: news

Benefits and Harms of Anticoagulation in Patients With AF Benefits and Harms of Anticoagulation in Patients With AF
This practice pearl presents decision rules to help determine the risk vs. benefit of anticoagulation therapy in patients with nonvalvular atrial fibrillation.American Family Physician (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 8, 2019 Category: Consumer Health News Tags: Family Medicine/Primary Care Journal Article Source Type: news

Acutus ‘Uncovers’ AcQMap’s Effectiveness with Trial Data
Data from the UNCOVER-AF trial reinforces the effectiveness of Acutus Medical’s AcQMap Imaging System in persistent atrial fibrillation (AF) ablation procedures. The Carlsbad, CA-based company released the data in late January at the 24th annual AF Symposium in Boston. AcQMap is a technology that combines charge mapping and high-resolution ultrasound imaging to create animated, 3D images in seconds that display anatomy and atrial arrhythmias. In the UNCOVER AF trial, investigators used AcQMap and a variety of on-market ablation technologies, to treat a total of 127 patients with de novo, persistent AF at...
Source: MDDI - February 6, 2019 Category: Medical Devices Authors: Omar Ford Tags: Business Imaging Source Type: news

J & J ’ s Biosense Webster launches IDE-cleared Qdot Micro RF ablation trial
Johnson & Johnson‘s (NYSE:JNJ) Biosense Webster said yesterday it launched a new FDA investigational device exemption study of its Qdot Micro radiofrequency ablation catheter exploring its use in treating symptomatic drug-refractory paroxysmal atrial fibrillation. The first patient in the trial has already been treated, with the procedure taking place at NYU Langone Health’s Heart Rhythm Center, the Irvine, Calif.-based J&J division said. “The delivery of 90 watts of RF power in a short, four-second ablation session is a significant advancement in the treatment of paroxysmal atrial fibri...
Source: Mass Device - February 5, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Clinical Trials Food & Drug Administration (FDA) johnsonandjohnson Source Type: news

AtriCure launches CryoIce persistent AF ablation trial
AtriCure (NSDQ:ATRC) said today that it launched a new FDA investigational device exemption cleared trial of its CryoIce system exploring its use in treating persistent atrial fibrillation during concomitant open-chested cardiac surgery. The first patient in the trial has already been treated, the Mason, Ohio-based company said. The initial procedure took place at Takoma Park, Md.’s Washington Adventist Hospital. “Cryothermal energy has been a mainstay of surgical ablation for a long time. The ICE-AFIB IDE trial is the first of its kind designed to assess the safety and sustained effectiveness of cryotherm...
Source: Mass Device - February 5, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Surgical AtriCure Inc. Source Type: news

First Atrial Fibrillation Patient Treated in Biosense Webster U.S. IDE Study Evaluating High Power, Short Duration Ablation Catheter
(Source: Johnson and Johnson)
Source: Johnson and Johnson - February 5, 2019 Category: Pharmaceuticals Source Type: news

Suicide attempt in patients with atrial fibrillation - a nationwide cohort study - Hu WS, Lin CL.
BACKGROUND AND AIMS: We analyze the incidence of suicide attempt in a Taiwanese population following admission to hospital between 2000 and 2010 for atrial fibrillation (AF). METHODS: Using a large National Health Insurance Research Database in Tai... (Source: SafetyLit)
Source: SafetyLit - February 4, 2019 Category: International Medicine & Public Health Tags: Suicide and Self-Harm Source Type: news

Feb 1 2019 This Week in Cardiology Feb 1 2019 This Week in Cardiology
New guidelines for atrial fibrillation, PFO closure for stroke prevention, fried chicken, skipping breakfast and e-cigarettes are discussed in this week ’ s podcast.theheart.org on Medscape (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 1, 2019 Category: Consumer Health News Tags: Cardiology Commentary Source Type: news

Special Report: Recording rhythms of the heart to prevent stroke
An implantable medical device assesses the risk of stroke in certain patients, though 98 percent of people with atrial fibrillation have no idea they have it. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - February 1, 2019 Category: Pharmaceuticals Authors: John Joyce Source Type: news

Long-Term Incidence of A-Fib Increased in Women With Breast Cancer
THURSDAY, Jan. 31, 2019 -- Women with breast cancer have an increased long-term incidence of atrial fibrillation (AF), according to a study published online Jan. 28 in Heart Rhythm. Maria D'Souza, M.D., from Copenhagen University Hospital... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 31, 2019 Category: Pharmaceuticals Source Type: news

Breast Cancer and Atrial Fibrillation: A'Multiple-Hit Phenomenon?'Breast Cancer and Atrial Fibrillation: A'Multiple-Hit Phenomenon? '
A nationwide study shows that the long-term incidence of atrial fibrillation (AF) is elevated in patients with breast cancer, and the short-term incidence is higher among younger women.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 29, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Acutus Medical touts 12-month AcQMap-guided AF ablation trial data
Acutus Medical today released 12-month data from the Uncover-AF trial of its AcQMap cardiac imaging and mapping system exploring its use in persistent atrial fibrillation ablation procedures. Results from the trial were presented at the 24th Annual AF Symposium in Boston, the Carlsbad, Calif.-based company said. Acutus Medical’s AcQMap system is designed to detect and display standard voltage-based and higher resolution charge-source maps, and is able to generate real-time, 3D images of the heart chamber using ultrasound. “We have mapped arrhythmias with the same technology for decades without asking if th...
Source: Mass Device - January 29, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Clinical Trials Acutus Medical Source Type: news

New blood thinners better than warfarin for atrial fibrillation
(Reuters Health) - Patients with atrial fibrillation, a common heart rhythm disorder, should take newer blood thinners to prevent stroke instead of the old standby drug warfarin, U.S. doctors recommend. (Source: Reuters: Health)
Source: Reuters: Health - January 29, 2019 Category: Consumer Health News Tags: healthNews Source Type: news

NOACs Recommended as First-Line Prevention of Stroke in A-Fib
TUESDAY, Jan. 29, 2019 -- For patients with atrial fibrillation, novel oral anticoagulants (NOACs) are recommended over warfarin to prevent stroke and weight loss is recommended for overweight and obese individuals, according to updated guidelines... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 29, 2019 Category: Pharmaceuticals Source Type: news

Breast Cancer May Bring Higher Odds for A-fib, Too
TUESDAY, Jan. 29, 2019 -- Women diagnosed with breast cancer may face a higher risk of developing the abnormal heartbeat called atrial fibrillation (a-fib), Danish researchers report. Breast cancer is the most common cancer among women worldwide. In... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 29, 2019 Category: General Medicine Source Type: news

Do women with breast cancer have a higher risk of atrial fibrillation?
(Elsevier) Patients with breast cancer may have an increased incidence of atrial fibrillation (AF), say researchers. A retrospective study in Denmark has found that women with breast cancer have an increased risk of developing AF within three years following their cancer diagnosis compared with other women of the same age. The results are published in HeartRhythm, the official journal of the Heart Rhythm Society and the Cardiac Electrophysiology Society. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - January 29, 2019 Category: Cancer & Oncology Source Type: news

New AFib Guidelines Advocate NOACs Over Warfarin
(MedPage Today) -- Weight loss also promoted for stroke prevention in atrial fibrillation (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - January 28, 2019 Category: American Health Source Type: news

Warfarin no longer recommended for most atrial fibrillation cases
The anti-clotting drug warfarin, commonly known as coumadin, is no longer recommended for the treatment of atrial fibrillation except for a select subset of patients, according to new guidelines just released by the American College of Cardiology and the American Heart Association. (Source: CNN.com - Health)
Source: CNN.com - Health - January 28, 2019 Category: Consumer Health News Source Type: news

AliveCor lands $20m loan from Oxford Finance
AliveCor landed a $20 million loan from Oxford Finance, the investment firm said today. Alexandria, Va.-based Oxford, which specializes in life-science and healthcare plays, said the senior secured loan are earmarked for working capital as Mountain View, Calif.-based AliveCor looks to expand the footprint of its mobile ECG devices. AliveCor makes the KardiaBand, a wrist-worn device is designed to detect atrial fibrillation, and the KardiaMobile app, a clinical-grade monitor that uses fingerpads to generate an ECG. “Heart disease is the leading cause of death in humans. AliveCor has developed low cost, hand-held ...
Source: Mass Device - January 28, 2019 Category: Medical Devices Authors: Brad Perriello Tags: Cardiovascular Featured Funding Roundup Patient Monitoring AliveCor Source Type: news

Cardiologist Groups Say Newer Blood Thinners Best Against A-Fib
MONDAY, Jan. 28, 2019 -- Newer blood thinners are recommended over warfarin for people with the heart condition called atrial fibrillation (a-fib) in updated treatment guidelines issued by three major American heart groups. The newer drugs are... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - January 28, 2019 Category: General Medicine Source Type: news

Medtronic to acquire cardiac ablation tech dev Epix Therapeutics
Medtronic (NYSE:MDT) said yesterday that it inked a deal to acquire cardiac ablation tech developer Epix Therapeutics, formerly known as Advanced Cardiac Therapeutics, for an undisclosed amount. Santa Clara, Calif.-based Epix’s flagship device is the DiamondTemp catheter-based radiofrequency cardiac ablation system, which won CE Mark approval in the European Union in 2017. The company is engaged in an FDA IDE trial of the device, the Diamond-AF trial, which it hopes will support regulatory clearance in the US with indications for treating patients with symptomatic paroxysmal atrial fibrillation. Epix added that ...
Source: Mass Device - January 25, 2019 Category: Medical Devices Authors: Fink Densford Tags: Business/Financial News Cardiovascular Catheters Featured Mergers & Acquisitions Advanced Cardiac Therapeutics Inc. Medtronic Source Type: news

UMN researchers refine the ability to predict atrial fibrillation-related stroke
(University of Minnesota Medical School) Atrial fibrillation (AFib) is associated with a five-fold increased risk of stroke. Nearly 3 million Americans are living with AFib. For years, researchers have been looking for ways to reduce the risk of stroke for this patient population. In a recent article published in Circulation, Lin Yee Chen, M.D., M.S., Associate Professor with tenure, Cardiovascular Division, in the Department of Medicine with the University of Minnesota Medical School demonstrates how to improve the prediction of stroke in patients with AFib. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 25, 2019 Category: International Medicine & Public Health Source Type: news

Abbott misses Wall Street expectations on Q4 sales
Abbott (NYSE:ABT) stock is down about 2% today after its fourth-quarter sales failed to meet analyst expectations. The Abbott Park, Ill.–based maker of medical device, pharmaceutical, nutrition and diagnostics products brought in about $7.765 billion in revenue in the quarter ended Dec. 31, 2018. The sales were up 2.3% from $7.589 billion earned during the same period a year ago but missed the $7.82 billion consensus of analysts polled on Yahoo! Finance. Earnings actually met expectations, and Abbott’s board in December even upped the company’s quarterly dividend 14.3%, to 32 cents per share. Fourth-...
Source: Mass Device - January 23, 2019 Category: Medical Devices Authors: Chris Newmarker Tags: Business/Financial News Featured News Well Wall Street Beat Abbott Source Type: news

Normal variations in thyroid function may be linked to atrial fibrillation risk
(Vanderbilt University Medical Center) A study by researchers at Vanderbilt University Medical Center has strengthened the link between thyroid function and atrial fibrillation (AF), an irregular heart rhythm that increases the risk of stroke and other heart-related complications. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 23, 2019 Category: International Medicine & Public Health Source Type: news

Abbott touts effective pain management, lower energy use in BurstDR SCS study results
Abbott (NYSE:ABT) late last week released results from a study of its BurstDR spinal cord stimulation technology, touting that it provided as effective pain relief as standard SCS despite providing lower-energy, intermittent stimulation known as “microdosing,” for patients with chronic intractable pain. Results from the BOLD study were presented at the 22nd Annual North American Neuromodulation Society Meeting in Las Vegas, the Chicago-area medtech company said. All patients in the BOLD trial reported experiencing pain relief with less than six hours of battery use per day while being treated with BurstDR,...
Source: Mass Device - January 22, 2019 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Featured Neuromodulation/Neurostimulation Pain Management Spinal Abbott Source Type: news

FDA clears Abbott ’ s TactiCath Sensor Enabled AF contact force ablation cath
Abbott (NYSE:ABT) said today that it won FDA approval for its TactiCath Sensor Enabled contact force ablation catheter intended for use in treating atrial fibrillation. The newly cleared TactiCath SE is intended to provide precise images of the heart overlaid with real-time electrical activity information, the Chicago-area medtech company said. The catheter also features an ergonomic design also used in the company’s FlexAbility catheter intended to improve reach and maneuverability. “Cardiac ablation has become a front-line therapy in the fight against conditions like atrial fibrillation in part because o...
Source: Mass Device - January 22, 2019 Category: Medical Devices Authors: Fink Densford Tags: Cardiovascular Catheters Featured Food & Drug Administration (FDA) Regulatory/Compliance Abbott Source Type: news

Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation
With approval of the TactiCath™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation ABBOTT PARK, Ill., Jan. 21, 2019 -- (Healt... Devices, Interventional, Cardiology, FDA Abbott, TactiCath, Ablation Catheter, atrial fibrillation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 21, 2019 Category: Pharmaceuticals Source Type: news

Abbott Offers a New Option for Physicians Treating Patients with Atrial Fibrillation
With approval of the TactiCath ™ Contact Force Ablation Catheter, Sensor Enabled™, Abbott is helping more physicians integrate ablation with 3D mapping to advance the treatment of people with atrial fibrillation (Source: Abbott.com)
Source: Abbott.com - January 21, 2019 Category: Pharmaceuticals Source Type: news

Alcohol and the Electric Atrium: How Drinking Promotes AF? Alcohol and the Electric Atrium: How Drinking Promotes AF?
Electrophysiologic studies are helping define the nature of atrial fibrillation's myocardial remodeling effects in moderate drinkers with the arrhythmia.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 18, 2019 Category: Consumer Health News Tags: Cardiology News Source Type: news

Sleep Apnea Device Maker Raises $11.5M with Private Placement
Electrophysiologists (EPs) who are managing atrial fibrillation (AF) patients who also suffer from sleep apnea have found that catheter ablation is most effective when used in conjunction with a CPAP regimen, yet there is a huge disconnect between the EPs and the sleep experts. That disconnect is what inspired Itamar Medical to develop SleePath, an integrated digital health sleep apnea care pathway monitoring system that allows cardiologists to monitor patients with AF sleep apnea status and compliance with CPAP devices on demand. The Caesarea, Isreal-based company unveiled SleePath last May at Heart Rhythm 201...
Source: MDDI - January 18, 2019 Category: Medical Devices Authors: Amanda Pedersen Tags: Business Source Type: news

Will a New J & amp;J and Apple Collaboration Lead to Better AFib Outcomes?
Johnson & Johnson’s Janssen Pharmaceuticals is teaming up with Apple for a research study to look at how to help improve atrial fibrillation (AFib) outcomes, including stroke prevention, through the use of wearables. The partnership will use an app developed by J&J along with the Cupertino, CA-based company’s Apple Watch. Recall in September of 2018, Apple received FDA clearance for an ECG app and another software-only mobile medical app analyzing pulse rates for irregular rhythms. Both companies said the multi-year research program will be launched later in 2019. This large-sca...
Source: MDDI - January 17, 2019 Category: Medical Devices Authors: Omar Ford Tags: Digital Health Cardiovascular Source Type: news

Johnson & Johnson, Apple ink collab for AFib study
Johnson & Johnson‘s (NYSE:JNJ) Janssen and Apple (NSDQ:AAPL) said today that the two companies inked a deal to study if an app from J&J in combination with the Apple Watch’s ECG app and irregular rhythm notifications can improve outcomes for people living with atrial fibrillation. The study is slated to measure the impact of the Apple Watch on the early detection and diagnosis of AFib, as well as the efficacy of a medication adherence program. Get the full story at our sister site, Drug Delivery Business News. The post Johnson & Johnson, Apple ink collab for AFib study appeared f...
Source: Mass Device - January 17, 2019 Category: Medical Devices Authors: Sarah Faulkner Tags: Business/Financial News Cardiovascular Drug-Device Combinations Featured mHealth (Mobile Health) Pharmaceuticals Wall Street Beat Apple Janssen Pharmaceuticals johnsonandjohnson Source Type: news

Johnson and Johnson Announces Research Study with Apple Watch to Help Improve AFib Outcomes Including Stroke Prevention
Johnson & Johnson to collaborate with Apple to assess impact of wearable technology on earlier detection of AFib, improved diagnosis and patient outcomes Up to 30 percent of AFib cases go undiagnosed until life-threatening complications occur, signaling... Devices, Cardiology, Monitoring Johnson & Johnson, Janssen Pharmaceuticals, Apple, atrial fibrillation (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 17, 2019 Category: Pharmaceuticals Source Type: news

Moderate Drinking Linked to Electroanatomic Changes in A-Fib
MONDAY, Jan. 14, 2019 -- Moderate alcohol consumption is associated with lower atrial voltage and conduction slowing in patients with atrial fibrillation (AF), according to a study published online Jan. 9 in Heart Rhythm. Aleksandr Voskoboinik,... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 14, 2019 Category: Pharmaceuticals Source Type: news

AF: Rate and Rhythm Control and Cognitive Performance AF: Rate and Rhythm Control and Cognitive Performance
Does controlling rate in older persons with atrial fibrillation affect cognition differently than controlling rhythm?Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - January 10, 2019 Category: Consumer Health News Tags: Cardiology Journal Article Source Type: news

How much is too much? Even moderate alcohol consumption is a risk factor for atrial fibrillation
(Elsevier) Excessive alcohol consumption is an established risk factor for atrial fibrillation (AF), but what are the effects of moderate and mild consumption on AF? In a new study published in HeartRhythm Australian researchers showed that regular moderate alcohol consumption (an average of 14 glasses per week) results in more electrical evidence of scarring and impairments in electrical signaling compared with non-drinkers and light drinkers. Alcohol consumption is therefore an important modifiable risk factor for AF. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - January 10, 2019 Category: International Medicine & Public Health Source Type: news

Should I make changes to my diet if I've been diagnosed with atrial fibrillation?
(Source: MayoClinic.com - Ask a Specialist)
Source: MayoClinic.com - Ask a Specialist - January 10, 2019 Category: Consumer Health News Source Type: news

Two new hormone biomarkers for atrial fibrillation
Research, published in theEuropean Heart Journal, suggests that brain natriuretic peptide and fibroblast growth factor-23 can improve the detection of atrial fibrillation, a condition that increases stroke risk. BBC (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 8, 2019 Category: Endocrinology Source Type: news

Two hormone biomarkers for atrial fibrillation
Research, published in theEuropean Heart Journal, suggests that the hormones brain natriuretic peptide and fibroblast growth factor-23 are biomarkers for atrial fibrillation, a condition that increases stroke risk. BBC (Source: Society for Endocrinology)
Source: Society for Endocrinology - January 8, 2019 Category: Endocrinology Source Type: news

iRhythm Finds Its Groove at the Intersection of Cardiology and AI
iRhythm Technologies has the distinct feature of being at the intersection of some of the hottest markets in medtech – cardiology, wearables, and artificial intelligence. The San Francisco-based company has developed, the Zio Patch XT, a wearable technology to monitor heart rate activity for up to 14 days and is set to present at the 37th Annual J.P. Morgan Healthcare Conference this week. Tim King, iRhythm’s president and CEO spoke to MD+DI ahead of the company’s presentation about the company's success and its goals going forward. “The tool of choice...
Source: MDDI - January 8, 2019 Category: Medical Devices Authors: Omar Ford Tags: Cardiovascular Digital Health Source Type: news

New device ‘will revolutionise’ atrial fibrillation treatment for one million Britons 
The AcQMap could revolutionise treatment for the one million Britons with atrial fibrillation. The device can detect where faulty heart beats are occurring, allowing treatment to be tailored. (Source: the Mail online | Health)
Source: the Mail online | Health - January 7, 2019 Category: Consumer Health News Source Type: news

Study finds risk factors and biomarkers to screen for AF
Researchers have found two biomarkers they say could be used in primary care to identify the heart condition atrial fibrillation in patients who have three clinical risk factors. (Source: Nursing Times)
Source: Nursing Times - January 7, 2019 Category: Nursing Source Type: news

Biomarkers identified to help diagnose heart condition
Atrial fibrillation is the most common heart rhythm disturbance, affecting 1.6m people in the UK. (Source: BBC News | Health | UK Edition)
Source: BBC News | Health | UK Edition - January 7, 2019 Category: Consumer Health News Source Type: news

Two biomarkers for atrial fibrillation identified
Researchers say biomarkers could be used to screen patients for the condition Related items fromOnMedica Daily aspirin not beneficial in healthy adults Regular GP pulse checks of elderly patients could prevent strokes, study finds (Source: OnMedica Latest News)
Source: OnMedica Latest News - January 7, 2019 Category: UK Health Source Type: news